Alimetry has developed a wearable, non-invasive medical device and app platform for the rapid and detailed diagnosis of a range of gastrointestinal disorders. Their objective measurement approach supersedes traditional “symptoms approach” diagnostics, reducing uncertainties, time, cost, and stress to both patients and clinicians.

Developed at the University of Auckland’s Bioengineering Institute, Alimetry is built on more than a decade of fundamental research in both clinical and academic settings, led by Professor Greg O’Grady as CEO. The company is working closely with Key Opinion Leaders (KOLs) within the GI field to establish their presence within the market through a record of performance excellence. Matū is committed to support the operational strategy and governance in the long-term, alongside investment partners IP Group and the University of Auckland Inventor’s Fund.